Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases.
Standard
Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. / Thoem, Ina; Schult-Kronefeld, Olaf; Burkholder, Iris; Schuch, Gunter; Andritzky, Birte; Kastendieck, Hartwig; Edler, Lutz; Wagener, Christoph; Bokemeyer, Carsten; Schumacher, Udo; Laack, Heinz-Eckart.
In: ANTICANCER RES, Vol. 29, No. 1, 1, 2009, p. 249-254.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases.
AU - Thoem, Ina
AU - Schult-Kronefeld, Olaf
AU - Burkholder, Iris
AU - Schuch, Gunter
AU - Andritzky, Birte
AU - Kastendieck, Hartwig
AU - Edler, Lutz
AU - Wagener, Christoph
AU - Bokemeyer, Carsten
AU - Schumacher, Udo
AU - Laack, Heinz-Eckart
PY - 2009
Y1 - 2009
N2 - BACKGROUND: CEACAM-1 is involved in intercellular adhesion and is expressed in a variety of human tissues. In cases of malignant transformation, a down-regulation or loss of CEACAM-1 has been shown. In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes. It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease. The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells. PATIENTS AND METHODS: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002. RESULTS: Expression of CEACAM-1 was shown in 78 out of 96 primary tumors (81.3%). A significant positive correlation was found between CEACAM-1 expression on cells of the primary tumor, lymph node metastases (p <0.005) and hematogenous metastases (p = 0.03). CEACAM-1 expression did not correlate with stage, gender, grading or patients' age. Compared to patients with tumors not expressing CEACAM-1, patients with a CEACAM-1-expressing tumor had a shorter median overall survival (21 vs. 28 months) and progression-free survival (11.7 vs. 16.3 months). CONCLUSION: CEACAM-1 is expressed in most primary pulmonary adenocarcinomas. This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites. These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma.
AB - BACKGROUND: CEACAM-1 is involved in intercellular adhesion and is expressed in a variety of human tissues. In cases of malignant transformation, a down-regulation or loss of CEACAM-1 has been shown. In contrast, CEACAM-1 is not expressed in normal lung tissue or melanocytes. It has been demonstrated that an expression in these tissues is associated with the development of metastatic disease. The aim of the present investigation was to analyze a possible association between the expression of CEACAM-1 in pulmonary adenocarcinomas and their lymph node and hematogenous metastatic cells. PATIENTS AND METHODS: CEACAM-1 expression was immunhistochemically evaluated in primary tumors, lymph nodes and distant metastases of 96 patients with metastatic pulmonary adenocarcinoma who had undergone surgery between 1999 and 2002. RESULTS: Expression of CEACAM-1 was shown in 78 out of 96 primary tumors (81.3%). A significant positive correlation was found between CEACAM-1 expression on cells of the primary tumor, lymph node metastases (p <0.005) and hematogenous metastases (p = 0.03). CEACAM-1 expression did not correlate with stage, gender, grading or patients' age. Compared to patients with tumors not expressing CEACAM-1, patients with a CEACAM-1-expressing tumor had a shorter median overall survival (21 vs. 28 months) and progression-free survival (11.7 vs. 16.3 months). CONCLUSION: CEACAM-1 is expressed in most primary pulmonary adenocarcinomas. This investigation demonstrates that its expression is preserved in lymph node and hematogenous metastases, indicating that its expression is of functional significance for both metastatic sites. These results support the prognostic relevance of the expression of CEACAM-1 in pulmonary adenocarcinoma.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 249
EP - 254
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 1
M1 - 1
ER -